Zahra Madjd

5.3k total citations
174 papers, 4.0k citations indexed

About

Zahra Madjd is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Zahra Madjd has authored 174 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Molecular Biology, 83 papers in Oncology and 36 papers in Cancer Research. Recurrent topics in Zahra Madjd's work include Cancer Cells and Metastasis (55 papers), Renal and related cancers (21 papers) and Cancer Genomics and Diagnostics (20 papers). Zahra Madjd is often cited by papers focused on Cancer Cells and Metastasis (55 papers), Renal and related cancers (21 papers) and Cancer Genomics and Diagnostics (20 papers). Zahra Madjd collaborates with scholars based in Iran, United States and Canada. Zahra Madjd's co-authors include Ian O. Ellis, Ian Spendlove, Lindy G. Durrant, Raheleh Roudi, Mojgan Asgari, Ahmad Shariftabrizi, Maryam Abolhasani, Nicholas FS Watson, Leili Saeednejad Zanjani and J H Scholefield and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Zahra Madjd

163 papers receiving 3.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zahra Madjd Iran 35 1.9k 1.7k 1.0k 931 477 174 4.0k
Lukas J.A.C. Hawinkels Netherlands 31 1.9k 1.0× 2.1k 1.2× 1.6k 1.6× 895 1.0× 590 1.2× 99 4.8k
Hidayatullah G. Munshi United States 45 2.3k 1.2× 2.5k 1.5× 803 0.8× 1.1k 1.2× 482 1.0× 106 4.8k
Paulette Mhawech‐Fauceglia United States 35 1.9k 1.0× 2.0k 1.2× 1.6k 1.6× 689 0.7× 676 1.4× 126 5.0k
Romain Boidot France 31 1.8k 1.0× 1.6k 1.0× 1.2k 1.2× 1.0k 1.1× 475 1.0× 112 4.0k
Fengxi Su China 29 2.3k 1.2× 2.2k 1.3× 1.5k 1.5× 1.7k 1.8× 449 0.9× 55 4.6k
Ann Zeuner Italy 35 2.4k 1.3× 1.4k 0.8× 879 0.9× 867 0.9× 275 0.6× 72 4.3k
Robert R. Langley United States 37 2.0k 1.1× 1.9k 1.1× 664 0.7× 908 1.0× 1.0k 2.1× 66 4.5k
Xiaofeng Jiang China 35 3.0k 1.6× 1.3k 0.8× 865 0.9× 984 1.1× 311 0.7× 73 4.4k
Karen E. Pollok United States 38 2.7k 1.5× 1.7k 1.0× 1.6k 1.6× 671 0.7× 387 0.8× 142 5.6k
Daniel J. Lindner United States 41 3.2k 1.7× 1.5k 0.9× 1.3k 1.3× 1.1k 1.2× 430 0.9× 133 5.4k

Countries citing papers authored by Zahra Madjd

Since Specialization
Citations

This map shows the geographic impact of Zahra Madjd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zahra Madjd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zahra Madjd more than expected).

Fields of papers citing papers by Zahra Madjd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zahra Madjd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zahra Madjd. The network helps show where Zahra Madjd may publish in the future.

Co-authorship network of co-authors of Zahra Madjd

This figure shows the co-authorship network connecting the top 25 collaborators of Zahra Madjd. A scholar is included among the top collaborators of Zahra Madjd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zahra Madjd. Zahra Madjd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Golshahi, Hannaneh, et al.. (2025). Placenta specific 1: a novel marker for detection of metastasis in mouse model of breast cancer. Biomarkers. 30(6). 394–406.
2.
Ghaffari, Aboozar, et al.. (2025). A High-resolution dataset for AI-driven segmentation and analysis of drug-treated breast tumor spheroids. Computer Methods and Programs in Biomedicine. 274. 109141–109141.
3.
Babajani, Amirhesam, et al.. (2025). Cytoplasmic SALL4-A isoform expression as a diagnostic marker of less aggressive tumor behavior in gastric cancer. World Journal of Surgical Oncology. 23(1). 41–41. 1 indexed citations
4.
Tajik, Fatemeh, et al.. (2024). Clinical significance of Talin-1 and HER-2 status in different types of gastric carcinoma. Biomarkers. 29(8). 539–556.
5.
6.
Fekri, Shiva, Lobat Geranpayeh, Hedieh Moradi Tabriz, et al.. (2023). Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With Breast Cancer. Clinical Breast Cancer. 24(1). e9–e19.e9.
7.
Azangou‐Khyavy, Mohammadreza, Javad Khanali, Babak Khorsand, et al.. (2023). Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study. Heliyon. 9(9). e19763–e19763. 17 indexed citations
8.
Asgari, Mojgan, Maryam Abolhasani, Mohammad Bahadoram, et al.. (2023). The Association of P53, CK29, and FGFR3 Overexpression with the Characteristics of Urothelial Cell Carcinoma of the Bladder. Asian Pacific Journal of Cancer Prevention. 24(9). 3125–3131. 3 indexed citations
9.
Madjd, Zahra, et al.. (2022). Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells. PLoS ONE. 17(12). e0279522–e0279522. 16 indexed citations
10.
Roudi, Raheleh, Ata Abbasi, Maryam Abolhasani, et al.. (2019). High GD2 expression defines breast cancer cells with enhanced invasiveness. Experimental and Molecular Pathology. 109. 25–35. 29 indexed citations
11.
Korourian, Alireza, et al.. (2019). Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma. Bratislavské lekárske listy/Bratislava medical journal. 120(1). 35–39. 17 indexed citations
12.
Kalantari, Elham, et al.. (2017). Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas. Pathology & Oncology Research. 23(4). 793–802. 39 indexed citations
13.
Roudi, Raheleh, Zahra Madjd, Marzieh Ebrahimi, Fazel Sahraneshin Samani, & Alí Samadikuchaksaraei. (2013). CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Cellular & Molecular Biology Letters. 19(1). 23–36. 40 indexed citations
14.
Madjd, Zahra, et al.. (2010). EXPRESSION OF BRCA1 PROTEIN IN INVASIVE AND IN SITU CARCINOMAS AND ITS RELATION WITH MARKER OF BREAST CANCER STEM CELLS (CD44) AND PROGNOSTIC FACTORS IN BREAST CANCER PATIENTS. Razi Journal of Medical Sciences. 17(8081). 16–24.
15.
Madjd, Zahra, et al.. (2009). OCT-4, an Embryonic Stem Cell Marker Expressed in Breast, Brain and Thyroid Carcinomas Compared to Testicular Carcinoma. Iranian Journal of Cancer Prevention. 2(4). 167–173. 2 indexed citations
16.
Asadi‐Lari, Mohsen, Zahra Madjd, & Mohammad Esmaeil Akbari. (2008). The need for palliative care services in Iran; an introductory commentary. Iranian Journal of Cancer Prevention. 1(1). 1–4. 10 indexed citations
17.
Asadi-Lari, Mohsen, et al.. (2008). Gaps in the provision of spiritual care for terminally ill patients in Islamic societies — a systematic review. Via Medica Journals. 7(2). 73–80. 9 indexed citations
18.
Asadi‐Lari, Mohsen, et al.. (2008). Spiritual care at the end of life in the Islamic context, a systematic review. Iranian Journal of Cancer Prevention. 1(2). 63–67. 12 indexed citations
19.
Madjd, Zahra, Ian Spendlove, Ian O. Ellis, S Pinder, & LG Durrant. (2005). Total Loss of MHC Class I is an Independent Indicator of Good Prognosis in Breast Cancer. SHILAP Revista de lepidopterología. 34. 51–52. 5 indexed citations
20.
Madjd, Zahra, et al.. (2005). Prognostic significance of SC101, a monoclonal Antibody against Lewisy/b in breast tumors. Cancer Research. 65. 360–361.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lukas J.A.C. Hawinkels Breakdown of academic impact, for papers by Hidayatullah G. Munshi Breakdown of academic impact, for papers by Paulette Mhawech‐Fauceglia Breakdown of academic impact, for papers by Romain Boidot Breakdown of academic impact, for papers by Fengxi Su Breakdown of academic impact, for papers by Ann Zeuner Breakdown of academic impact, for papers by Robert R. Langley Breakdown of academic impact, for papers by Xiaofeng Jiang Breakdown of academic impact, for papers by Karen E. Pollok Breakdown of academic impact, for papers by Daniel J. Lindner
Rankless by CCL
2026